Abstract
COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.
Keywords:
SARS-CoV-2; SPIKE protein; Vaccine.
MeSH terms
-
Animals
-
Antibodies, Viral / adverse effects
-
Antibodies, Viral / biosynthesis
-
Antibody-Dependent Enhancement / immunology
-
Betacoronavirus / genetics
-
Betacoronavirus / immunology*
-
Betacoronavirus / pathogenicity
-
COVID-19
-
COVID-19 Vaccines
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / genetics
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control*
-
Humans
-
Pandemics / prevention & control*
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control*
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus / chemistry
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology*
-
Translational Research, Biomedical
-
Viral Vaccines / adverse effects
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
Substances
-
Antibodies, Viral
-
COVID-19 Vaccines
-
Spike Glycoprotein, Coronavirus
-
Viral Vaccines
-
spike protein, SARS-CoV-2